Cell therapy weekly: stem cell therapy for ALS fails late-stage clinical trial

This week: a Phase III trial evaluating NurOwn® as a treatment for amyotrophic lateral sclerosis reports disappointing results, positive top-line results have been reported from a Phase III gene therapy trial in patients with hemophilia B, a partnership is announced to advance the mass production of iPSC-derived hematopoietic stem cell transplants, and an additional site has begun enrolling patients into a Phase I/II trial of Zofin™ for COVID-19. The news headlines: Stem cell therapy for ALS fails late-stage clinical trial Phase III gene therapy trial demonstrates positive results in patients with hemophilia B Partnership announced to scale-up manufacturing of iPS-derived...